Started a BRAF Colorectal Cancer Public Library group on Facebook. So many significant trials, research findings, changes to NCCN guidelines, etc. in the last 2 years. Gathering high level research/interviews into 1 place seems wise and useful. #BRAFCRC https://t.co/1FjFjY9AOU

Congratulations to Dr. Scott Kopetz! @RueschCenter chose well for the 2025 Luminary Award! Really easy to say a lot of great things about Dr. @skopetz ... but, really -- it's all so true and his career has been so impactful for BRAF colorectal cancer patients around the world.

Now is your last chance to register for the Pittsburgh Third Annual GI Cancer Summit! We will soon be gathering to discuss the latest research and insights. If you are thinking of making last-minute plans, be sure to register via the link below.

Dr. @smitha42 @FightCRC Research #ASCO25 updates discussed DSP107, a first-in-class bi-specific 4-1BB T-cell engager, w/ & w/o atezolizumab in MSS mCRC pts NOW: Phase 2b trial to open 10 US/Australian sites NCT07235293 PI: @AnwaarSaeed3 at 35 minutes https://t.co/Q918WPoMuT

new title for the trial at @MSKCC_OncoNotes A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy NCT07227636

$SMMT Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer https://t.co/NAlWagqOnU

✔️In summary AI literacy roadmap for Oncologists Start with awarenes and foundational knowledge. Thankful to @myESMO for this inaugural conference 🧬🤖 #ESMOAI25

𝗙𝗶𝗻𝗱𝗶𝗻𝗴 𝘁𝗵𝗲 𝗕𝗲𝘀𝘁 𝗗𝗿𝘂𝗴 𝗳𝗼𝗿 𝗮 𝗦𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗖𝗮𝗻𝗰𝗲𝗿: 𝗮𝗻 𝗨𝗽𝗱𝗮𝘁𝗲 𝗼𝗻 𝗧𝗿𝗮𝘃𝗲𝗿𝗮 | #CuriousDrGeorge & Dennis Watson, VP Business Development of Travera: https://t.co/HRo0ANarXS #CancerGuidance #CancerTreatment #PrecisionOncology #TraveraRTG

more countries! be the first or second profile from yours! Note: future development so patients can search by multiple countries Hoping of use for oncologists in the community with heart - but little time for research.

Apropos of 1st #ESMOAI25 A Canadian Stage IV colorectal cancer patient developed a FREE trial matching website - w/ AI matching & explanations. Initially just for Canada, https://t.co/2HWZGN9ydY, now global. Launched 11/1/25 Matches in minutes @myESMO https://t.co/oQaIBD9ahG

🎯 “From variant to value.” @loic_verlingue shares how multimodal AI assistants are transforming the Molecular Tumor Board — integrating genomics, imaging & clinical data into one intelligent layer to guide truly precision oncology decisions. #ESMOAI25

Here at #ESMOAI25 presenting two abstracts 👾 205P — an in-house automated pipeline, for detecting #CRC recurrence from radiological reports in EMR using LLMs 👾 313P — six-month feasibility study evaluated AYABYTES, a mobile health application co-designed to support AYA

🤖 Attending #ESMOAI25? When posting from or about the congress, don't forget to use #ESMOAI25 to join the conversation and connect with the global oncology community. #HealthAI

Delighted to see this! MINIMAL RESIDUAL DISEASE TRIAL Phase II Study of Adjuvant Botensilimab in Comb W/ Balstilimab in Pts W/ Colorectal Cancer & Persistent Circulating Tumor DNA Following Surgery & Chemotherapy 284 pts Kudos to @MSKCancerCenter @segaln @ldiaz1971 #MRD

A phase 1 study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in patients (pts) with advanced solid tumors including colorectal cancer: Updated dose-escalation part NCT03833700. #GI23 #CRCSM https://t.co/PkQ7QqXiSW

Enrollment is now open for our randomized dose optimization study of E7386 in combination with other anticancer drug(s) in patients with endometrial carcinoma.

Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025 $STRO

🚨 #ESMO25 #mCRC – Phase II OPTIPRIME (FFCD 1605) explored a stop-and-go FOLFOX + panitumumab strategy in RAS/BRAF WT mCRC (n=115) 🎯 Median duration of disease control = 24.9 mo (90% CI 19.3–28.3) 💥ORR 74.8% at induction → 45% 1st reintro → 25% later reintros ▪️OS 36.1 mo

727MO: OPTIPRIME study, FOLFOX + Pani "stop-and-go" strategy ✅Duration of disease control 24.9 mo ✅1st re-introduction ORR: 45.0% ✅OS 36.1 mo 👉Want to know toxicity profiles including neuropathy with oxaliplatin re-introduction #ESMO25 @myESMO @OncoAlert

Amazing slide from @DrArturoAI

A Prospective Feasibility Study Using ctDNA to Tailor Neoadjuvant Chemotherapy for Patients With Colorectal or Appendiceal Adenocarcinoma At @MDAndersonNews PI: Michael White, MD Opened December 2024 ctDNA testing before CRS or HIPEC NCT05947838 https://t.co/5R3VtMAphF #CRCSM